Glucagon receptor antagonism induces increased cholesterol absorption
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Glucagon and insulin have opposing action in governing glucose homeostasis. In type 2 diabetes mellitus (T2DM), plasma glucagon is characteristically elevated, contributing to increased gluconeogenesis and hyperglycemia. Therefore, glucagon receptor (GCGR) antagonism has been proposed as a pharmacologic approach to treat T2DM. In support of this concept, a potent small-molecule GCGR antagonist (GRA), MK-0893, demonstrated dose-dependent efficacy to reduce hyperglycemia, with an HbA1c reduction of 1.5% at the 80 mg dose for 12 weeks in T2DM. However, GRA treatment was associated with dose-dependent elevation of plasma LDL-cholesterol (LDL-c). The current studies investigated the cause for increased LDL-c. We report findings that link MK-0893 with increased glucagon-like peptide 2 and cholesterol absorption. There was not, however, a GRA-related modulation of cholesterol synthesis. These findings were replicated using structurally diverse GRAs. To examine potential pharmacologic mitigation, coadministration of ezetimibe (a potent inhibitor of cholesterol absorption) in mice abrogated the GRA-associated increase of LDL-c. Although the molecular mechanism is unknown, our results provide a novel finding by which glucagon and, hence, GCGR antagonism govern cholesterol metabolism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Following 68 weeks of treatment, semaglutide impressively lowered body weight in non-diabetic, obese individuals by 14.9%, relative to 2.4% in placebo-treated controls68.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [68]
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Role of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
Davis, H. R., Zhu, L.-J., Hoos, L. M., Tetzloff, G., Maguire, M., Liu, J., Yao, X., Iyer, S. P. N., Lam, M.-H., Lund, E. G., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405817200 · Cited by 615
Self-citationGelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Human Insulin Resistance Is Associated With Increased Plasma Levels of 12α-Hydroxylated Bile Acids
Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D., & Ferrannini, E. (2013) · Diabetes · doi:10.2337/db13-0639 · Cited by 444
Bosner, M. S., Lange, L. G., Stenson, W. F., & Ostlund, R. E. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33370-8 · Cited by 310
Howard, B. V., Robbins, D. C., Sievers, M. L., Lee, E. T., Rhoades, D., Devereux, R. B., Cowan, L. D., Gray, R. S., Welty, T. K., Go, O. T., et al. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.3.830 · Cited by 301
Bilheimer, D. W., Goldstein, J. L., Grundy, S. M., & Brown, M. S. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108223 · Cited by 244
Molecular mechanisms underlying bile acid‐stimulated glucagon‐like peptide‐1 secretion
Parker, H., Wallis, K., le Roux, C., Wong, K., Reimann, F., & Gribble, F. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01561.x · Cited by 227
Glucagon-Like Peptide-2 Increases Intestinal Lipid Absorption and Chylomicron Production via CD36
Hsieh, J., Longuet, C., Maida, A., Bahrami, J., Xu, E., Baker, C. L., Brubaker, P. L., Drucker, D. J., & Adeli, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.05.051 · Cited by 216
Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men
Miettinen, T. A., Tilvis, R. S., & Kesäniemi, Y. A. (1989) · Metabolism · doi:10.1016/0026-0495(89)90252-7 · Cited by 213
Herold, K. C., Gitelman, S. E., Willi, S. M., Gottlieb, P. A., Waldron-Lynch, F., Devine, L., Sherr, J., Rosenthal, S. M., Adi, S., Jalaludin, M. Y., et al. (2013) · Diabetologia · doi:10.1007/s00125-012-2753-4 · Cited by 159
Ni, Y. G., Marco, S. D., Condra, J. H., Peterson, L. B., Wang, W., Wang, F., Pandit, S., Hammond, H. A., Rosa, R., Cummings, R. T., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m011445 · Cited by 146
Self-citationTurley, S. D., Herndon, M. W., & Dietschy, J. M. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41221-0 · Cited by 143
PANCREATIC ALPHA-CELL FUNCTION IN RELATION TO CHOLESTEROL METABOLISM*
CAREN, R., & CARBO, L. (1956) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-16-4-507 · Cited by 143
Validation of a dual-isotope plasma ratio method for measurement of cholesterol absorption in rats
Zilversmit, D. B., & Hughes, L. B. (1974) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36766-3 · Cited by 141
Patient perspectives on once‐weekly medications for diabetes
Polonsky, W. H., Fisher, L., Hessler, D., Bruhn, D. F., & Best, J. H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01327.x · Cited by 139
GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production
Hein, G. J., Baker, C., Hsieh, J., Farr, S., & Adeli, K. (2012) · Diabetes · doi:10.2337/db12-0202 · Cited by 135
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis
Ali, S., Lamont, B. J., Charron, M. J., & Drucker, D. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43615 · Cited by 119
Alrefai, W. A., Annaba, F., Sarwar, Z., Dwivedi, A., Saksena, S., Singla, A., Dudeja, P. K., & Gill, R. K. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00306.2006 · Cited by 112
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
Tremblay, A. J., Lamarche, B., Lemelin, V., Hoos, L. M., Benjannet, S., Seidah, N. G., Davis, J. H. R., & Couture, P. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m011080 · Cited by 111
Kelly, R. P., Garhyan, P., Raddad, E., Fu, H., Lim, C. N., Prince, M. J., Pinaire, J. A., Loh, M. T., & Deeg, M. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12446 · Cited by 110
Gu, W., Yan, H., Winters, K. A., Komorowski, R., Vonderfecht, S. L., Atangan, L. I., Sivits, G. N., Hill, D., Yang, J., Bi, V., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157685 · Cited by 109
Drucker, D. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7386 · Cited by 97
Xiong, Y., Guo, J., Candelore, M. R., Liang, R., Miller, C., Dallas-Yang, Q., Jiang, G., McCann, P. E., Qureshi, S. A., Tong, X., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300579z · Cited by 87
Self-citationPersson, L., Gälman, C., Angelin, B., & Rudling, M. (2009) · Endocrinology · doi:10.1210/en.2008-1281 · Cited by 86
Hypolipemic action of glucagon in experimental endogenous lipemia in the rat
Eaton, R. P. (1973) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36889-9 · Cited by 86
Castro-Perez, J., Briand, F., Gagen, K., Wang, S.-P., Chen, Y., McLaren, D. G., Shah, V., Vreeken, R. J., Hankemeier, T., Sulpice, T., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m016410 · Cited by 80
Self-citationRudling, M., & Angelin, B. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116522 · Cited by 76
Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin
Lakoski, S. G., Xu, F., Vega, G. L., Grundy, S. M., Chandalia, M., Lam, C., Lowe, R. S., Stepanavage, M. E., Musliner, T. A., Cohen, J. C., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1952 · Cited by 74
Cholic acid supplementation enhances cholesterol absorption in humans
Woollett, L. A., Buckley, D. D., Yao, L., Jones, P. J. H., Granholm, N. A., Tolley, E. A., Tso, P., & Heubi, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.058 · Cited by 69
Sudhop, T., Reber, M., Tribble, D., Sapre, A., Taggart, W., Gibbons, P., Musliner, T., von Bergmann, K., & Lütjohann, D. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p900004-jlr200 · Cited by 67
Headspace analyses of acetone: A rapid method for measuring the 2H-labeling of water
Shah, V., Herath, K. B., Previs, S. F., Hubbard, B. K., & Roddy, T. P. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.05.010 · Cited by 61
Self-citationBlockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes
Engelking, L. J., McFarlane, M. R., Li, C. K., & Liang, G. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m027599 · Cited by 60
Edwards, P. A., Lemongello, D., & Fogelman, A. M. (1979) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40644-3 · Cited by 53
Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models
Vuguin, P. M., & Charron, M. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01447.x · Cited by 52
Mu, J., Qureshi, S. A., Brady, E. J., Muise, E. S., Candelore, M. R., Jiang, G., Li, Z., Wu, M. S., Yang, X., Dallas-Yang, Q., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049572 · Cited by 50
Self-citationDallas-Yang, Q., Shen, X., Strowski, M. Z., Brady, E. J., Saperstein, R., Gibson, R. E., Szalkowski, D., Qureshi, S. A., Candelore, M. R., Fenyk-Melody, J. E., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.08.023 · Cited by 40
Effects of glucagon on plasma lipids in different types of primary hyperlipoproteinemia
Aubry, F., Marcel, Y. L., & Davignon, J. (1974) · Metabolism · doi:10.1016/0026-0495(74)90061-4 · Cited by 40
Regulation of Mouse Intestinal L Cell Progenitors Proliferation by the Glucagon Family of Peptides
Grigoryan, M., Kedees, M. H., Charron, M. J., Guz, Y., & Teitelman, G. (2012) · Endocrinology · doi:10.1210/en.2012-1120 · Cited by 37
Han, S., Akiyama, T. E., Previs, S. F., Herath, K., Roddy, T. P., Jensen, K. K., Guan, H.-P., Murphy, B. A., McNamara, L. A., Shen, X., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m035592 · Cited by 34
Self-citationGlucagon and cholesterol metabolism.
Caren, R., & Corbo, L. (1960) · PubMed · Cited by 32
Hepatic Niemann–Pick C1-like 1
Pramfalk, C., Jiang, Z., & Parini, P. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283468c28 · Cited by 29
Intestinal sterol transporters and cholesterol absorption inhibition
Davis, H. R., Tershakovec, A. M., Tomassini, J. E., & Musliner, T. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834c7c28 · Cited by 28
Self-citationPrevis, S. F., Mahsut, A., Kulick, A. A., Dunn, K., Andrews-Kelly, G., Johnson, C., Bhat, G., Herath, K. B., Miller, P. L., Wang, S., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.d014993 · Cited by 28
Self-citationZhou, H., Li, W., Wang, S.-P., Mendoza, V., Rosa, R. L., Hubert, J. A., Herath, K. B., McLaughlin, T. M., Rohm, R. J., Lassman, M. E., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.d021295 · Cited by 28
Self-citationGeneration of mice expressing the human glucagon receptor with a direct replacement vector
Shiao, L., Cascieri, M. A., Trumbauer, M. E., Chen, H., & Sullivan, K. A. (1999) · Transgenic Research · doi:10.1023/a:1008922521461 · Cited by 26
Jensen, K. K., Previs, S. F., Zhu, L., Herath, K. B., Wang, S., Bhat, G., Hu, G., Miller, P. L., McLaren, D. G., Shin, M. K., et al. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00436.2011 · Cited by 21
Self-citationWang, S., Daniels, E., Chen, Y., Castro‐Perez, J. M., Zhou, H., Akinsanya, K., Previs, S. F., Roddy, T. P., & Johns, D. G. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m041541 · Cited by 19
Self-citationBenefits of lipid-lowering therapy in patients with type 2 diabetes mellitus
Betteridge, J. D. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.013 · Cited by 18
Research works printed but not linked: 6
- Engel, 2011, Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM), Diabetes., 60, A85
- Engel, 2012, Glycemic and lipid effects of the short-acting glucagon receptor antagonist MK-3577 in patients with type 2 diabetes, Diabetes., 61, A266
- Kazda, 2013, The glucagon receptor antagonist LY2409021 significantly lowers HbA1c and is well tolerated in patients with type 2 diabetes mellitus: a 24-week phase 2 study, Diabetologia., 56, S391
- Morgan, 2014, ISIS-GCGRRX, an antisense glucagon receptor antagonist, caused rapid, robust, and sustained improvements in glycemic control without changes in BW, BP, lipids, or hypoglycemia in T2DM patients on stable metformin therapy, Diabetes., 63, LB28
- Engel, 2011, Efficacy and safety of the glucagon receptor antagonist, MK-0893, in combination with metformin or sitagliptin in patients with type 2 diabetes mellitus, Diabetologia., 54, S86
- Drucker, 2001, Glucagon-like peptide 2, J. Clin. Endocrinol. Metab., 86, 1759
Cited by
Regulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,133
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“The most common associated effects in the preclinical studies are the development of hyperglucagonemia and increased -cell proliferation, but there is also preclinial and clinical evidence indicating that GcGR antagonism may increase plasma levels of total and LDL cholesterol (245, 342).”
BackgroundTargeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
A large electronic-health-record-based genome-wide study of serum lipids
Hoffmann, T. J., Theusch, E., Haldar, T., Ranatunga, D. K., Jorgenson, E., Medina, M. W., Kvale, M. N., Kwok, P.-Y., Schaefer, C., Krauss, R. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0064-5 · Cited by 297
“Although a role for the pancreas in LDL-metabolism has not been established, glucagon, a hormone synthesized in pancreatic islet alpha cells, has been reported to decrease intestinal cholesterol absorption 59 .”
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
“Glucagon receptor antagonists have been associated with increased cholesterol absorption from the gut.(218)”
Background
Metadata
- Authors
- Guan, H.-P., Yang, X., Lu, K., Wang, S.-P., Castro-Perez, J. M., Previs, S., Wright, M., Shah, V., Herath, K., Xie, D., Szeto, D., Forrest, G., Xiao, J. C., Palyha, O., Sun, L.-P., Andryuk, P. J., Engel, S. S., Xiong, Y., Lin, S., Kelley, D. E., Erion, M. D., Davis, H. R., & Wang, L.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Guan, Hong-Ping
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 56
- Issue
- 11
- Pages
- 2183-2195
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4617405
- OpenAlex
- W2179944903
- Cited by
- 76
- References
- 56
- Citations by year
- 2025: 6 · 2024: 7 · 2023: 3 · 2022: 8 · 2021: 11 · 2020: 5 · 2019: 6 · 2018: 15 · 2017: 9 · 2016: 6
- FWCI
- 10.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1799 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes, LDL cholesterol elevation, cholesterol absorption, ezetimibe, glucagon-like peptide-2, cholesterol metabolism, hyperglycemia, glucose homeostasis
- MeSH terms
- Animals, Cholesterol, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Humans, Hypercholesterolemia, Intestinal Absorption, Male, Mice, Inbred C57BL, Mice, Transgenic, Naphthalenes, Pyrazoles, beta-Alanine, Receptors, Glucagon, Inhibitory Concentration 50
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.